Randomized clinical trial of a combination of an inhaled corticosteroid and beta agonist in patients at risk of developing the acute respiratory distress syndrome

Critical Care Medicine

Volumn 45, Issue 5, 2017, Pages 798-805

  Festic, Emir ^a   Carr, Gordon E ^b   Cartin Ceba, Rodrigo ^c   Hinds, Richard F ^d   Banner Goodspeed, Valerie ^e   Bansal, Vikas ^a   Asuni, Adijat T ^f   Talmor, Daniel ^e   Rajagopalan, Govindarajan ^g   Frank, Ryan D ^a   Gajic, Ognjen ^d   Matthay, Michael A ^h   Levitt, Joseph E ^f  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d MAYO CLINIC   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MAYO GRADUATE SCHOOL   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute lung injury; Acute respiratory distress syndrome; Budesonide; Formoterol; Prevention

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; PLACEBO; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL MARKER; CORTICOSTEROID; OXYGEN;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AEROSOL; AGED; ARTICLE; ARTIFICIAL VENTILATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EMERGENCY WARD; FEASIBILITY STUDY; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OXYGEN SATURATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNITED STATES; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; HYPOXIA; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; PATIENT ACUITY; RESPIRATORY DISTRESS SYNDROME, ADULT; RISK FACTOR; UNIVERSITY HOSPITAL; VERY ELDERLY;

ACADEMIC MEDICAL CENTERS; ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; AGED; AGED, 80 AND OVER; BIOMARKERS; BUDESONIDE, FORMOTEROL FUMARATE DRUG COMBINATION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOXIA; MALE; MIDDLE AGED; OXYGEN; PATIENT ACUITY; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, ADULT; RISK FACTORS; UNITED STATES;

EID: 85014022390     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000002284     Document Type: Article

References (34)

1. Ashbaugh DG, Bigelow DB, Petty TL, et al: Acute respiratory distress in adults. Lancet 1967; 2:319-323.
2. Villar J, Blanco J, Añón JM, et al; ALIEN Network: The ALIEN study: Incidence and outcome of acute respiratory distress syndrome in the era of lung protective ventilation. Intensive Care Med 2011; 37:1932-1941.
3. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000; 342:1301-1308.
4. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network; Wiedemann HP, Wheeler AP, Bernard GR, et al: Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006; 354:2564-2575.
5. Papazian L, Forel JM, Gacouin A, et al; ACURASYS Study Investigators: Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 2010; 363:1107-1116.
6. Steinberg KP, Hudson LD, Goodman RB, et al; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network: Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006; 354:1671-1684.
7. National Heart Lung Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network; Matthay MA, Brower RG, Carson S, et al: Randomized, placebo-controlled clinical trial of an aerosolized beta2-Agonist for treatment of acute lung injury. Am J Respir Crit Care Med 2011; 184:561-568.
8. National Heart L, Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network; Truwit JD, Bernard GR, Steingrub J, et al: Rosuvastatin for sepsis-Associated acute respiratory distress syndrome. N Engl J Med 2014; 370:2191-2200.
9. Spragg RG, Bernard GR, Checkley W, et al: Beyond mortality: Future clinical research in acute lung injury. Am J Respir Crit Care Med 2010; 181:1121-1127.
10. Gajic O, Dabbagh O, Park PK, et al; U.S. Critical Illness and Injury Trials Group: Lung Injury Prevention Study Investigators (USCIITGLIPS): Early identification of patients at risk of acute lung injury: Evaluation of lung injury prediction score in a multicenter cohort study. Am J Respir Crit Care Med 2011; 183:462-470.
11. Festic E, Bansal V, Kor DJ, et al; US Critical Illness and Injury Trials Group: Lung Injury Prevention Study Investigators (USCIITG-LIPS): Spo2/Fio2 ratio on hospital admission is an indicator of early acute respiratory distress syndrome development among patients at risk. J Intensive Care Med 2015; 30:209-216.
12. Bernard GR, Luce JM, Sprung CL, et al: High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 1987; 317:1565-1570.
13. Meduri GU, Tolley EA, Chrousos GP, et al: Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome: Evidence for inadequate endogenous glucocorticoid secretion and inflammationinduced immune cell resistance to glucocorticoids. Am J Respir Crit Care Med 2002; 165:983-991.
14. Meduri GU, Golden E, Freire AX, et al: Methylprednisolone infusion in early severe ARDS: Results of a randomized controlled trial. Chest 2007; 131:954-963.
15. Gao Smith F, Perkins GD, Gates S, et al; BALTI-2 study investigators: Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): A multicentre, randomised controlled trial. Lancet 2012; 379:229-235.
16. Perkins GD, Gates S, Park D, et al; BALTI-Prevention Collaborators: The beta agonist lung injury trial prevention. A randomized controlled trial. Am J Respir Crit Care Med 2014; 189:674-683.
17. Ju NY, Gao H, Huang W, et al: Therapeutic effect of inhaled budesonide (Pulmicort® Turbuhaler) on the inflammatory response to one-lung ventilation. Anaesthesia 2014; 69:14-23.
18. Walther S, Jansson I, Berg S, et al: Corticosteroid by aerosol in septic pigs-effects on pulmonary function and oxygen transport. Intensive Care Med 1993; 19:155-160.
19. Jansson AH, Eriksson C, Wang X: Effects of budesonide and N-Acetylcysteine on acute lung hyperinflation, inflammation and injury in rats. Vascul Pharmacol 2005; 43:101-111.
20. Wang J, Zhang L, Walther SM: Administration of aerosolized terbutaline and budesonide reduces chlorine gas-induced acute lung injury. J Trauma 2004; 56:850-862.
21. Suda K, Tsuruta M, Eom J, et al: Acute lung injury induces cardiovascular dysfunction: Effects of IL-6 and budesonide/formoterol. Am J Respir Cell Mol Biol 2011; 45:510-516.
22. Spindler V, Waschke J: Beta-Adrenergic stimulation contributes to maintenance of endothelial barrier functions under baseline conditions. Microcirculation 2011; 18:118-127.
23. Festic E, Ortiz-Diaz E, Lee A, et al; United States Critical Illness and Injury Trials Group: Lung Injury Prevention Study Investigators (USCIITG-LIPS): Prehospital use of inhaled steroids and incidence of acute lung injury among patients at risk. J Crit Care 2013; 28:985-991.
24. Mangi AM, Bansal V, Li G, et al: Pre-hospital use of inhaled corticosteroids and inhaled beta agonists and incidence of ARDS: A population- based study. Acta Med Acad 2015; 44:109-116.
25. The ARDS Definition Task Force: Acute respiratory distress syndrome: The Berlin Definition. JAMA 2012; 307:2526-2533.
26. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94:496-509.
27. Rice TW, Wheeler AP, Bernard GR, et al; National Institutes of Health, National Heart, Lung, and Blood Institute ARDS Network: Comparison of the Spo2/Fio2 ratio and the Pao2/Fio2 ratio in patients with acute lung injury or ARDS. Chest 2007; 132:410-417.
28. Jones HA, Turner SL, Hughes JM: Performance of the large-reservoir oxygen mask (Ventimask). Lancet 1984; 1:1427-1431.
29. Torres A, Sibila O, Ferrer M, et al: Effect of corticosteroids on treatment failure among hospitalized patients with severe communityacquired pneumonia and high inflammatory response: A randomized clinical trial. JAMA 2015; 313:677-686.
30. Blum CA, Nigro N, Briel M, et al: Adjunct prednisone therapy for patients with community-Acquired pneumonia: A multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2015; 385:1511-1518.
31. Siemieniuk RA, Meade MO, Alonso-Coello P, et al: Corticosteroid therapy for patients hospitalized with community-Acquired pneumonia: A systematic review and meta-Analysis. Ann Intern Med 2015; 163:519-528.
32. Matthay MA, Folkesson HG, Clerici C: Lung epithelial fluid transport and the resolution of pulmonary edema. Physiol Rev 2002; 82:569-600.
33. Prescott HC, Calfee CS, Thompson BT, et al: Toward smarter lumping and smarter splitting: Rethinking strategies for sepsis and acute respiratory distress syndrome clinical trial design. Am J Respir Crit Care Med 2016; 194:147-155.
34. Kor DJ, Carter RE, Park PK, et al; US Critical Illness and Injury Trials Group: Lung Injury Prevention with Aspirin Study Group (USCIITG: LIPS-A): Effect of aspirin on development of ARDS in at-risk patients presenting to the emergency department: The LIPS-A randomized clinical trial. JAMA 2016; 315:2406-2414.